Sugi Predict

Sugi Predict / Targets / P2RX4

P2RX4

P2X purinoceptor 4 · Q99571 · P2RX4 on Sugi Atlas →

51,290 patent compounds predicted against P2RX4, 31,240 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Carbamazepine Carbamazepine (SCHEMBL21639) 0.74 16/20
Carbamazepine Carbamazepine (SCHEMBL157648) 0.48 16/20
SCHEMBL220840 SCHEMBL220840 0.59 15/20
SCHEMBL220994 SCHEMBL220994 0.54 15/20
SCHEMBL220291 SCHEMBL220291 0.58 14/20
SCHEMBL179726 SCHEMBL179726 0.56 14/20
SCHEMBL47007 SCHEMBL47007 0.48 13/20
Oxcarbazepine Oxcarbazepine (SCHEMBL321371) 0.51 12/20
SCHEMBL349029 SCHEMBL349029 0.35 10/20
SCHEMBL179725 SCHEMBL179725 0.50 9/20
Imd-0354 Imd-0354 (SCHEMBL129165) 1.00 8/20
SCHEMBL330263 SCHEMBL330263 0.75 8/20
Carbamazepine Epoxide Carbamazepine Epoxide (SCHEMBL156675) 0.42 8/20
SCHEMBL126928 SCHEMBL126928 0.42 8/20
SCHEMBL130143 SCHEMBL130143 1.00 7/20
SCHEMBL330059 SCHEMBL330059 0.90 7/20
SCHEMBL131758 SCHEMBL131758 0.85 7/20
SCHEMBL330023 SCHEMBL330023 0.70 7/20
SCHEMBL131425 SCHEMBL131425 0.66 7/20
SCHEMBL214110 SCHEMBL214110 0.60 7/20

Clinical trials — most relevant to P2RX4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine PHASE4COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor PHASE4COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease PHASE2/PHASE3COMPLETED
Botulinum Toxin Injections for Oral Neuropathic Pain PHASE3COMPLETED
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks PHASE3WITHDRAWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383 PHASE1UNKNOWN
First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160. PHASE1COMPLETED
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects PHASE1COMPLETED
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion EARLY_PHASE1NOT_YET_RECRUITING
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults EARLY_PHASE1COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients nanRECRUITING
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients nanCOMPLETED
The Real-world Treatment Satisfaction by Gefapixiant in RCC nanRECRUITING
Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.) nanCOMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder nanCOMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy nanENROLLING_BY_INVITATION
Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients nanCOMPLETED
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. nanCOMPLETED
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis nanRECRUITING
Translational Study of the Effects of Neural Mobilization in Patients With Lomboisquiatalgia nanCOMPLETED
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Investigation of the Pruritogens of Liver-related Diseases nanUNKNOWN
ATP and P2X3 Receptor in Chronic Cough nanUNKNOWN
P2X7 Receptor, Inflammation and Neurodegenerative Diseases nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RX4 binder may also engage these)

ProteinNameSimilarity
Q5E9U1 — 1.000 Q5E9U1 →
Q9JJX6 — 1.000 Q9JJX6 →
P51577 — 0.998 P51577 →
P2RX1 P2X purinoceptor 1 0.994 landscape →
P2RX5 P2X purinoceptor 5 0.989 landscape →
P51576 — 0.988 P51576 →
P47824 — 0.985 P47824 →
P2RX3 P2X purinoceptor 3 0.984 landscape →
F8W463 — 0.984 F8W463 →
Q91VE2 — 0.981 Q91VE2 →
P51579 — 0.981 P51579 →
P49654 — 0.981 P49654 →
O54803 — 0.979 O54803 →
Q3UR32 — 0.979 Q3UR32 →
P51578 — 0.978 P51578 →
P30715 — 0.977 P30715 →
P18597 — 0.977 P18597 →
Q202B1 — 0.976 Q202B1 →
ATP4B Potassium-transporting ATPase subunit beta (G 0.975 landscape →
P51165 — 0.974 P51165 →
P33704 — 0.974 P33704 →
P05029 — 0.974 P05029 →
Q9GLC3 — 0.974 Q9GLC3 →
Q9BDK6 — 0.973 Q9BDK6 →
Q3T0C6 — 0.972 Q3T0C6 →
Q8VEK0 — 0.972 Q8VEK0 →
Q9UN42 — 0.972 Q9UN42 →
P18434 — 0.972 P18434 →
P43002 — 0.972 P43002 →
Q24048 — 0.971 Q24048 →